REBEKAH SVADLENKA: Open Payments
NPI 1063003895 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$340 in 22 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $339 · 2025 $340
Food & beverage: $340
| Company | Payments | Amount |
|---|---|---|
| Corium, LLC | 7 | $70 |
| Tris Pharma Inc | 3 | $61 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $55 |
| Alkermes, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
Products named: Azstarys, REXULTI, Dyanavel XR, Qelbree, UZEDY, ARISTADA, INVEGA SUSTENNA, REJOYN.
Industry payments across ID — which companies pay providers there.
